I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Ciccarone Center Research
View by Topic
- Antiplatelet Therapy
- ASCVD (Atherosclerotic Cardiovascular Disease)
- Blood Pressure
- Cardiac CT
- Cardiovascular Risk Assessment
- Carotid Atherosclerosis
- Cerebrovascular Disease / Stroke / Cognitive Function
- Cholesterol / Lipids / Statins
- Cigarette Smoking
- Diabetes & Metabolic Syndrome
- Diet & Weight
- Disparities in Care
- Emotional Health
- Endothelial Function
- Erectile Dysfunction
- Exercise and Physical Fitness
- Family History of CVD
- Gender / Cardiovascular Disease in Women
- Heart Failure
- Heart Rate
- Markers of Thrombosis, Myocardial Injury, Wall Stress
- Mobile Health
- Nutrition, Vitamins, Supplements
- PVD – Peripheral Vascular Disease
- Quality of Care
- Renal Disease
- Rheumatoid Arthritis & Collagen Vascular Diseases
- Sleep Disorders
- Stem Cells
- Subclinical Atherosclerosis
- Vascular Imaging
- Vascular Stiffness
View by Journal
- American Heart Journal
- American Journal of Cardiology
- American Journal of Epidemiology
- American Journal of Hypertension
- Annals of Internal Medicine
- Arteriosclerosis, Thrombosis & Vascular Biology
- British Medical Journal
- Clinical Cardiology
- Diabetes Care
- European Heart Journal
- European Journal of Preventive Cardiology
- International Journal of Cardiology
- Journal of Hypertension
- Journal of the American College of Cardiology
- Journal of the American Heart Association
- Journal of the American Medical Association
- Mayo Clinic Proceedings
- New England Journal of Medicine
- PLoS One
View by Year
- Meet the Authors
Rheumatoid Arthritis & Collagen Vascular Diseases
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.
Cardiovascular disease remains the major cause of death in systemic lupus erythematosus (SLE). We assessed the degree to which cardiovascular risk factors and disease activity were associated with 2-year changes in measures of subclinical atherosclerosis. Our data did not provide evidence of an association between measures of SLE disease activity (SLEDAI, anti-dsDNA, anti-phospholipid and treatment) and progression of subclinical atherosclerosis. Age and hypertension were associated with the progression of carotid IMT and plaque. Age, smoking and cholesterol were associated with progression of CAC.
Lupus Atherosclerosis Prevention Study (LAPS).
CVD is one of the major causes of death in SLE. A study (200 patients with SLE without clinical CVD randomized to receive atorvastatin 40 mg daily or an identical placebo) was undertaken to investigate whether treatment with statins would reduce subclinical measures of atherosclerosis over a 2-year period. However, this study provided no evidence that atorvastatin reduces subclinical measures of atherosclerosis or disease activity over 2 years in patients with SLE. In fact, it does not reduce biochemical measures of inflammation. The anti-inflammatory effects of statins observed in the general population were not replicated in this SLE clinical trial.
Abdominal obesity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics.
Abdominal adiposity, especially visceral adiposity, is emerging as a recognized cardiometabolic risk factor. This study was undertaken to investigate how abdominal fat is distributed in rheumatoid arthritis (RA), and its RA-related determinants. We compared men and women with RA with non-RA controls from MESA. The distribution of abdominal fat differs significantly by RA status. Higher VFA in men with RA, and the more potent association of VFA with cardiometabolic risk factors in men and women with RA, may contribute to cardiovascular risk in RA populations.
Abdominal adiposity in rheumatoid arthritis: Association with cardiometabolic risk factors and disease characteristics.
The distribution of abdominal fat differs significantly by rheumatoid arthritis (RA) status. Higher visceral fat area (VFA) in men with RA, and the more potent association of VFA with cardiometabolic risk factors in men and women with RA, may contribute to cardiovascular risk in RA populations.
Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging.
Heart failure is a major contributor to cardiovascular morbidity and mortality in patients with RA, but little is known about myocardial structure and function in this population. This study suggests that the progression to heart failure in RA may occur through reduced myocardial mass rather than hypertrophy. Both modifiable and nonmodifiable factors may contribute to lower levels of left ventricular mass and volume.
Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific.
Compared to controls, RA was associated with a higher prevalence and higher severity of atherosclerosis in the bulb-ICA but not the CCA. Our data suggest that future studies in RA that utilize carotid artery measurements should include assessment of the bulb-ICA.